Lilly takes legal action against sellers marketing unapproved knockoffs of its experimental GLP-1 drug retatrutide, highlighting ongoing black market concerns f

FDA approves the first cereblon E3 ligase modulator (CELMoD) for multiple myeloma, a new drug class for the blood cancer.

Novo Nordisk's CEO pushes back on zero-sum thinking in the obesity drug market, as competition with Lilly intensifies and analysts adjust outlooks.

A small study of Eledon's islet cell therapy achieved insulin independence in all 12 treated patients, a potential breakthrough in type 1 diabetes.

Senator Warren demands transparency from HHS Secretary RFK Jr on drug price negotiations conducted under the Trump administration's drug pricing initiative.

Lilly launches a program offering its obesity medications to Medicare beneficiaries for $50 a month, aiming to improve affordability.

Pharma companies reduce reimbursement filings in Switzerland citing concerns that US most-favored-nation pricing policies could be applied to Swiss drug access.

The cost-effectiveness watchdog ICER concludes that AstraZeneca's novel hypertension drug is priced too high relative to its clinical benefit.

Australia's Health Minister pushes for PBS listing of GLP-1 drugs, but budget estimates warn of a potential A$10 billion fiscal impact from broad subsidies.

Biopharma sector saw strong second-quarter sales led by Eli Lilly, Sanofi, Regeneron, and Astellas.

Candel Therapeutics reports interim data showing a 39% improvement in disease-free survival for its prostate cancer therapy.

FDA assigns a PDUFA date of April 2027 for Inhibrx's ozekibart, setting up a decision on the experimental therapy.

Investigations and industry commentary highlight the growing problem of counterfeit and unapproved retatrutide being sold illegally online.

GRAIL shares are volatile as the market awaits an FDA decision on its Galleri multi-cancer early detection test.

Indian regulators mandate that new drugs not approved anywhere in the world must undergo a complete domestic review process before market entry.

A recent FDA clearance for Tempus AI's diagnostic platform is expected to open the door to broader insurance reimbursement.

Analysis suggests Pfizer shares are undervalued after the company raised its full-year revenue guidance.

Bluejay Therapeutics finishes enrollment in its Phase 2b trial of an anti-IL-6 therapy, with results expected.